Navigation Links
ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Date:6/29/2009

- Final manufacturing activities for ANX-530 NDA re-started

SAN DIEGO, June 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced its plans for the remainder of 2009.

Following the financing that closed earlier this month, ADVENTRX has re-started the final manufacturing activities related to submitting an NDA for ANX-530. In addition, the Company will continue to evaluate the data from its recently-completed bioequivalence study of ANX-514 and plans to seek a meeting with the FDA to discuss the results. For the near-term, the Company intends to maintain its cost-efficient and flexible infrastructure by engaging consultants on a project basis and outsourcing substantially all of its development activities to specialized vendors and contract development organizations.

"We believe ANX-530 has a clear path to NDA submission that involves a small number of remaining activities and our recent financing allowed us to very quickly re-start much of that work, as well as to continue to evaluate the best path forward for ANX-514. An update on our NDA submission timeline will be provided as critical activities are completed; however, our goal is to submit the NDA around the end of 2009," said Brian M. Culley, Chief Business Officer at ADVENTRX. "The extensive market research and analysis we commissioned from independent third-parties suggests there is an attractive market opportunity in the U.S. for ANX-530, which market can be accessed with a small, cost-effective sales organization."

"Given the limited cost of the remaining development activities leading to an NDA submission, we determined that the value of ANX-530 to our stockholders would be maximized by raising the necessary capital to move forward independently. This decision and our ability to file the NDA r
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury verdict ... excess of $10 million. The jury determined that Genewiz ... it improperly hired one or more of GenScript,s employees.  ... notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... 2015 Protiviti ( www.protiviti.com ), a global ... Governance Portal , designed to increase the efficiency ... tasks across multiple business units and projects. The Governance ... better align their controls with the COSO ( Committee ... In response to client feedback, Protiviti has also included ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape is ... arena, Frost & Sullivan will host its 20 th ... MindXchange , March 8 to 10, at the Hilton San ... This event is a platform for ... to discuss industry disruptions and how to succeed in an ...
(Date:2/26/2015)... 26, 2015 RURO, Inc., a leading ... version 6.2 – the latest update to the bestselling ... that of a quick and easy method to gain ... latest version, RURO engineering has enhanced the system’s support ... large amounts of sample records. , "FreezerPro has ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2
... 2010 , , , ... Women Biologists, Chemists, Physicists and,Mathematicians Recognized Across the Developing World , ... The Elsevier Foundation, TWAS and TWOWS announced today that they are,recognizing ... Latin America and the Caribbean for their research excellence. The,announcement was ...
... ORLANDO, Fla. , June 26, 2010 ... and Company (NYSE: LLY ) today announced results ... ® (exenatide) injection added to Lantus ® (insulin ... targets without weight gain or increasing their risk of hypoglycemia. ...
... June 25 Interleukin Genetics, Inc. (NYSE Amex: ... , it received notification from the Corporate Compliance Staff of ... to initiate proceedings to delist the Company,s common stock because ... Exchange,s Company Guide due to stockholders, equity of less than ...
Cached Biology Technology:Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 2Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 3Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 4Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 5Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 6Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 7Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 2Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 3Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 4Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 5Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 6Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 7Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 8Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex 2
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... smell the coffee and enjoy a cup of it ... get your juices flowing. It might keep you going for ... cyclist, University of Illinois kinesiology and community health professor Robert ... fuel up on caffeine prior to hitting the pavement on ...
... a genetic engineering breakthrough that could help everyone from bed-ridden ... Nobel Prize winner Mario R. Capecchihave created a "switch" that ... muscle stem cells to monitor muscle regeneration in a living ... switch, or drug, that allows people to grow new muscle ...
... CA--A Cancer Genomics Browser developed by researchers at the ... to visualize and analyze data from studies aimed at ... of the disease. The browser consists of ... find patterns in the huge amounts of clinical and ...
Cached Biology News:A little java makes it easier to jive, researcher says 2A little java makes it easier to jive, researcher says 3A little java makes it easier to jive, researcher says 4Stem cell breakthrough: Monitoring the on switch that turns stem cells into muscle 2Cancer Genomics Browser gives cancer researchers a powerful new tool 2Cancer Genomics Browser gives cancer researchers a powerful new tool 3Cancer Genomics Browser gives cancer researchers a powerful new tool 4
RABBIT ANTI RAT AQUAPORIN 5...
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
Recombinant Rat CINC-2 beta, CF...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
Biology Products: